Tirzepatide
approvedDual GLP-1/GIP receptor agonist for weight loss and metabolic health
Availability in Thailand
Tirzepatide is available in Thailand through peptide vendors and select private clinics in Bangkok. Branded pharmaceutical pens have limited availability compared to semaglutide, while research-grade formulations are more widely accessible through online vendors with domestic shipping. Availability is expanding as demand grows.
Prescription: Branded pens may require clinic consultation. Research-grade tirzepatide is available from vendors without prescription.
Legal status: Not Thai FDA-approved as a pharmaceutical, but available as a research peptide. Not a controlled substance.
⚠️ As with all research-grade peptides, verify third-party testing results and certificates of analysis (COAs) before purchasing. Ensure proper cold-chain storage.
Where to Buy in Thailand
Tirzepatide pricing in Thailand varies significantly by source (vendor vs clinic) and dosage. Check vendor and clinic websites directly for current rates.
Vendors
Clinics
Peptides Thailand (Boston Health Longevity)
Chiang Mai
Peptide therapy programs with medical supervision
View clinic →Overview
Tirzepatide is a dual-action peptide that activates both GLP-1 and GIP receptors simultaneously — often called a 'twincretin.' By targeting two incretin hormone pathways instead of one, it produces significantly greater weight loss than single-target GLP-1 agonists like semaglutide. Clinical trials demonstrated average weight loss of up to 22.5% of body weight, and a head-to-head trial showed roughly 47% more weight loss compared to semaglutide.
How It Works
GIP receptor activation (primary target)
Tirzepatide binds GIP receptors with affinity equal to native GIP. GIP receptor activation enhances insulin secretion, modulates lipid metabolism, and influences fat distribution and energy balance. GIP may also have antiemetic properties, which could explain why tirzepatide tends to have a more tolerable side effect profile than pure GLP-1 agonists.
GLP-1 receptor activation (secondary target)
Tirzepatide activates GLP-1 receptors with approximately five times weaker affinity than native GLP-1. This activates appetite suppression, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The biased signalling at GLP-1 receptors — favouring cAMP over β-arrestin — may contribute to improved efficacy and tolerability.
Synergistic dual mechanism
The combination of GIP and GLP-1 activation produces metabolic improvements exceeding what either pathway achieves alone. Studies show greater insulin sensitivity, more pronounced weight reduction, and favourable effects on lipid profiles and liver fat compared to GLP-1-only compounds.
Protocol Quick Reference
Benefits & Uses
- Superior weight loss: Clinical trials demonstrated average weight loss of 20.9% at the highest dose over 72 weeks — the highest achieved by any currently approved anti-obesity medication
- Outperforms semaglutide: Head-to-head trial (SURMOUNT-5) showed approximately 47% more weight loss than semaglutide
- Blood sugar control: Reduces HbA1c by 1.24–2.58% in clinical trials, with up to 62% of patients reaching normal blood sugar levels
- Improved lipid profile: Reduces total cholesterol, LDL, and triglycerides while increasing HDL cholesterol
- Liver fat reduction: Significant reductions in liver fat content, relevant for metabolic-associated fatty liver disease
- Better GI tolerability: Many users report milder nausea compared to semaglutide, possibly due to GIP's balancing effect
Side Effects
Common
- Nausea — generally milder than with pure GLP-1 agonists, possibly due to GIP's antiemetic properties
- Diarrhea
- Constipation
- Decreased appetite
- Vomiting — most common during dose escalation phases
Less Common
- Injection site reactions
- Fatigue
- Hair thinning (reported by some users during rapid weight loss — not specific to tirzepatide)
Serious
- Pancreatitis — seek immediate medical attention for severe, persistent abdominal pain
- Gallbladder disease
- Hypoglycemia — particularly when combined with insulin or sulfonylureas
- Thyroid C-cell tumour concerns — class warning from rodent studies; avoid with personal/family history of medullary thyroid carcinoma
- Not recommended during pregnancy
Related Peptides
FAQ
Is tirzepatide available in Thailand?▼
Yes. Branded pharmaceutical pens have limited availability through select private clinics in Bangkok. Research-grade tirzepatide is more widely accessible through peptide vendors with domestic Thai shipping. Availability is expanding as demand increases.
How much does tirzepatide cost in Thailand?▼
Tirzepatide pricing in Thailand varies significantly by source. Research-grade from peptide vendors is the most affordable option, while branded pens through clinics cost considerably more. Check vendor and clinic websites directly for current pricing as it changes frequently.
Is tirzepatide better than semaglutide for weight loss?▼
Clinical data suggests tirzepatide produces greater average weight loss — approximately 20-22% vs 15% for semaglutide. A head-to-head trial confirmed roughly 47% more weight loss with tirzepatide. However, individual responses vary, and semaglutide has a longer track record and broader Thai availability at lower cost.
Can I switch from semaglutide to tirzepatide?▼
Yes, many people who plateau on semaglutide successfully switch to tirzepatide. You would typically start at the 2.5 mg adaptation dose regardless of your previous semaglutide dose. Discuss the transition with your healthcare provider.
How quickly does tirzepatide work?▼
Appetite suppression typically begins within the first week, even at the 2.5 mg starting dose. Visible weight loss usually becomes apparent within 4-8 weeks. Peak results accumulate over 12-18 months of sustained use at therapeutic doses.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Peptides should be used under the guidance of a qualified healthcare professional. Individual results vary. Always consult your doctor before starting any peptide therapy.